Ризедронат Тева 35 мг

Pays: Israël

Langue: russe

Source: Ministry of Health

Achète-le

Ingrédients actifs:

RISEDRONIC ACID AS SODIUM 35 MG

Disponible depuis:

ABIC MARKETING LTD

Code ATC:

M05BA07

forme pharmaceutique:

TABLETS

Mode d'administration:

PER OS

Fabriqué par:

TEVA PHARMACEUTICAL WORKS PRIVATE LIMITED COMPANY, HUNGARY

Groupe thérapeutique:

RISEDRONIC ACID

indications thérapeutiques:

Treatment of postmenopausal osteoporosis to reduce the risk of vertebral fractures. Treatment of established postmenopausal osteoporosis to reduce the risk of hip fractures. Prevention of osteoporosis in postmenopausal women with increased risk of osteoporosis. Treatment of osteoporosis in men at high risk of fracture.

Date de l'autorisation:

2011-10-01

Documents dans d'autres langues

Notice patient Notice patient anglais 18-03-2018
Notice patient Notice patient arabe 18-03-2018
Notice patient Notice patient hébreu 18-03-2018

Rechercher des alertes liées à ce produit